Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Barinthus Biotherapeutics's annualized net income for the quarter that ended in Mar. 2026 was €-19.14 Mil. Barinthus Biotherapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €48.39 Mil. Therefore, Barinthus Biotherapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -39.54%.
The historical rank and industry rank for Barinthus Biotherapeutics's Return-on-Tangible-Equity or its related term are showing as below:
STU:2AB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -79.08 Med: -47.43 Max: 2.6
Current: -72.95
During the past 7 years, Barinthus Biotherapeutics's highest Return-on-Tangible-Equity was 2.60%. The lowest was -79.08%. And the median was -47.43%.
STU:2AB's Return-on-Tangible-Equity is ranked worse than 64.58% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs STU:2AB: -72.95
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Barinthus Biotherapeutics Return-on-Tangible-Equity Related Terms
Barinthus Biotherapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Barinthus Biotherapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2AB vs VTGN, PSTV, PVCT: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -39.54% mean?
Barinthus Biotherapeutics (STU:2AB) has a Return-on-Tangible-Equity of -39.54% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Barinthus Biotherapeutics and its competitors. According to the industry distribution chart, Barinthus Biotherapeutics ranks #775 out of 1200 companies in the Biotechnology industry, placing it in the top 64.6%.
Is Barinthus Biotherapeutics' Return-on-Tangible-Equity too high?
Barinthus Biotherapeutics' current Return-on-Tangible-Equity is -39.54%. Based on the distribution chart, Barinthus Biotherapeutics ranks #775 out of 1200 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Return-on-Tangible-Equity compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #775 out of 1200 companies for Return-on-Tangible-Equity. This places Barinthus Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Return-on-Tangible-Equity is -39.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Return-on-Tangible-Equity of -39.54%. The stock's GF Value™ is €0.96, compared to a current price of €0.57 — trading 41.1% below its estimated fair value. The current Return-on-Tangible-Equity is -39.54%. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Return-on-Tangible-Equity is -39.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.57 is trading 41.1% below its estimated GF Value™ of €0.96.
Key valuation signals for STU:2AB:
Return-on-Tangible-Equity: -39.54%
GF Value™: €0.96 vs. price of €0.57 (41.1% below fair value)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
